1,3-二氢-1-苯基-3-(4-吡啶基甲基)-2H-吲哚-2-酮 | 105431-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1,3-二氢-1-苯基-3-(4-吡啶基甲基)-2H-吲哚-2-酮
• 英文名称: 1,3-dihydro-1-phenyl-3-(4-pyridinylmethyl)-2H-indol-2-one
• 英文别名: 1-phenyl-3-(pyridin-4-ylmethyl)-3H-indol-2-one
• CAS: 105431-73-0
• 化学式: C₂₀H₁₆N₂O
• 分子量: 300.36
• InChiKey: PMDRWYRDPTXUPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  539.8±39.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-二氢-1-苯基-3-(4-吡啶基甲基)-2H-吲哚-2-酮 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 1,3-二氢-3-羟基-1-苯基-3-(吡啶基甲基)-2H-吲哚-2-酮
  参考文献：
  名称：

  3-Substituted 3-(4-pyridinylmethyl)-1,3-dihydro-1-phenyl-2H-indol-2-ones as acetylcholine release enhancers: synthesis and SAR

  摘要：

  A series of 3-substituted, 3-(4-pyridinylmethyl)-1,3-dihydro-1-phenyl-2H-indol-2-ones was synthesized and found to enhance the stimulus-induced release of neurotransmitter acetylcholine (AcCh), and by doing so, might be useful in treating cognitive disorders where the level of this neurotransmitter may be diminished in the brain, as in Alzheimer's disease. An attempt has been made to correlate the structure of the 3-substitution with the ability of the compounds to enhance the release of AcCh from the striatum region of rat brain preparations.

  DOI：

  10.1021/jm00072a009
• 作为产物：
  描述：

  1,3-二氢-3-羟基-1-苯基-3-(吡啶基甲基)-2H-吲哚-2-酮 在 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 甲醇 、 溶剂黄146 、 异丙醇 为溶剂， 反应 2.0h， 生成 1,3-二氢-1-苯基-3-(4-吡啶基甲基)-2H-吲哚-2-酮
  参考文献：
  名称：

  A Large Scale Preparation of the Cognitive Enhancer Linopirdine

  摘要：

  Linopirdine is a pharmacologically potent drug which stimulates central nervous system neurotransmitter release. A facile process used to synthesize linopirdine on a commercial manufacturing scale consisting of seven chemical steps with only a single isolated intermediate is described.

  DOI：

  10.1080/00397919308011258

文献信息

• Human kcnq5 potassium channel, methods and compositions thereof
  申请人：——

  公开号：US20020040000A1

  公开（公告）日：2002-04-04

  An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses. Moreover, the hKCNQ5 polypeptide can be used to assay for KCNQ5 potassium channel modulators, which can be utilized in the treatment of neurological, neurophysiological, neuropsychological and neuroaffective diseases, conditions and disorders, including, but not limited to, acute and chronic pain, migraine, acute stroke, dementia, vascular dementia, trauma, epilepsy, amyelotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's Disease, learning and cognitive disorders, and neurophysiological disorders including anxiety disorders, depression, bipolar disorders, sleep disorders, addiction, and eating disorders.

  本文描述了一种编码新型钾通道多肽 KCNQ5 的分离多核苷酸，KCNQ5 主要在大脑和骨骼肌中表达。这种新的多肽是从人脑 cDNA 文库中克隆和分离出来的，是钾通道 KCNQ 家族的成员。所提供的人 KCNQ5 核酸序列和编码的多肽可用于诊断、筛选和治疗。此外，hKCNQ5 多肽还可用于检测 KCNQ5 钾通道调节剂，而 KCNQ5 钾通道调节剂可用于治疗神经、神经生理、神经心理和神经情感性疾病、病症和紊乱，包括但不限于急性和慢性疼痛、偏头痛、急性中风、痴呆、血管性痴呆、脑卒中、颅内出血、颅内感染、颅内压增高、颅内压增高和颅内压增高、急性中风、痴呆、血管性痴呆、创伤、癫痫、肌萎缩性脊髓侧索硬化症（ALS）、多发性硬化症（MS）、帕金森病、学习和认知障碍以及神经生理障碍，包括焦虑症、抑郁症、双相情感障碍、睡眠障碍、成瘾和饮食失调。
• Human voltage-gated potassium channel subunit
  申请人：——

  公开号：US20040038890A1

  公开（公告）日：2004-02-26

  A novel human voltage-gated potassium channel subunit is provided. A full length cDNA which encodes the novel potassium channel polypeptide is disclosed as well as the interior structural region and the amino acid residue sequence of the voltage-gated potassium channel biomolecule. Methods are provided to identify compounds that modulate the pharmacological activity of the potassium channel subunit and hence regulate potassium channel biological activity.

  本研究提供了一种新型人类电压门控钾通道亚基。 公开了编码新型钾通道多肽的全长 cDNA 以及电压门控钾通道生物大分子的内部结构区和氨基酸残基序列。 还提供了鉴定可调节钾通道亚基药理活性从而调节钾通道生物活性的化合物的方法。
• Human KCNQ5 potassium channel, methods and compositions thereof
  申请人：Dworetzky I. Steven

  公开号：US20050064491A1

  公开（公告）日：2005-03-24

  An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses. Moreover, the hKCNQ5 polypeptide can be used to assay for KCNQ5 potassium channel modulators, which can be utilized in the treatment of neurological, neurophysiological, neuropsychological and neuroaffective diseases, conditions and disorders, including, but not limited to, acute and chronic pain, migraine, acute stroke, dementia, vascular dementia, trauma, epilepsy, amyelotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's Disease, learning and cognitive disorders, and neurophysiological disorders including anxiety disorders, depression, bipolar disorders, sleep disorders, addiction, and eating disorders.

  本文描述了一种编码新型钾通道多肽 KCNQ5 的分离多核苷酸，KCNQ5 主要在大脑和骨骼肌中表达。这种新的多肽是从人脑 cDNA 文库中克隆和分离出来的，是钾通道 KCNQ 家族的成员。所提供的人 KCNQ5 核酸序列和编码的多肽可用于诊断、筛选和治疗。此外，hKCNQ5 多肽还可用于检测 KCNQ5 钾通道调节剂，而 KCNQ5 钾通道调节剂可用于治疗神经、神经生理、神经心理和神经情感性疾病、病症和紊乱，包括但不限于急性和慢性疼痛、偏头痛、急性中风、痴呆、血管性痴呆、脑卒中、颅内出血、颅内感染、颅内压增高、颅内压增高和颅内压增高、急性中风、痴呆、血管性痴呆、创伤、癫痫、肌萎缩性脊髓侧索硬化症（ALS）、多发性硬化症（MS）、帕金森病、学习和认知障碍以及神经生理障碍，包括焦虑症、抑郁症、双相情感障碍、睡眠障碍、成瘾和饮食失调。
• Pierce, Michael E.; Huhn, George F.; Jensen, James H., Journal of Heterocyclic Chemistry, 1994, vol. 31, # 1, p. 17 - 24
  作者：Pierce, Michael E.、Huhn, George F.、Jensen, James H.、Sigvardson, Ken W.、Islam, Qamrul、Xing, Yide

  DOI：——

  日期：——
• Synthetic Communications 1993, 23, 1617-1625
  作者：

  DOI：——

  日期：——